Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Darotropium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 20/20 | 0.97 |
| ▸ | CHRM2 known ✓ | P08172 | 4/20 | 0.97 |
| ▸ | CHRM1 known ✓ | P11229 | 4/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Darotropium SCHEMBL3682092 | 1.00 | CHRM3 (0.97) | CHRM3CHRM2CHRM1 | |
| Darotropium SCHEMBL16781068 | 1.00 | CHRM3 (0.97) | CHRM3CHRM2CHRM1 | |
| Darotropium SCHEMBL29504618 | 1.00 | CHRM3 (0.97) | CHRM3CHRM2CHRM1 | |
| Darotropium SCHEMBL524037 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1 | |
| Darotropium SCHEMBL29355152 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1 | |
| Darotropium SCHEMBL146665 | 0.99 | CHRM3 (0.94) | CHRM3CHRM2CHRM1 | |
| Darotropium SCHEMBL140647 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1 | |
| Darotropium SCHEMBL140648 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1 | |
| Darotropium SCHEMBL146666 | 0.99 | CHRM3 (0.94) | CHRM3CHRM2CHRM1 | |
| Bromide SCHEMBL4631510 | 0.93 | CHRM3 (0.90) | CHRM3CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100329996-A1 | Novel Combination of Therapeutic Agents | GLAXO GROUP LIMITED | 2010-12-30 | — | — | US | claimed |
| EP-2197444-A1 | NOVEL COMBINATION OF THERAPEUTIC AGENTS | Glaxo Group Limited (GB) | 2010-06-23 | — | — | EP | claimed |
| WO-2009036243-A1 | NOVEL COMBINATION OF THERAPEUTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2009-03-19 | — | — | WO | claimed |
| US-20100329996-A1 | Novel Combination of Therapeutic Agents | GLAXO GROUP LIMITED | 2010-12-30 | — | — | US | disclosed |
| US-20100329996-A1 | Novel Combination of Therapeutic Agents | GLAXO GROUP LIMITED | 2010-12-30 | — | — | US | disclosed |
| WO-2010097114-A1 | NOVEL COMBINATION OF THERAPEUTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2010-09-02 | — | — | WO | disclosed |
| EP-2197444-A1 | NOVEL COMBINATION OF THERAPEUTIC AGENTS | Glaxo Group Limited (GB) | 2010-06-23 | — | — | EP | disclosed |
| US-7579361-B2 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2009-08-25 | — | — | US | disclosed |
| US-7576096-B2 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2009-08-18 | — | — | US | disclosed |
| WO-2009036243-A1 | NOVEL COMBINATION OF THERAPEUTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2009-03-19 | — | — | WO | disclosed |
| EP-1851201-A1 | 1-{4-[(1-CYCLOBUTYL-4-PIPERIDINYL)OXY]PHENYL}-4-{[4-(METHYLSULFONYL)PHENYL]CARBONYL}PIPERAZINE AS HISTAMINE H3 ANTAGONIST | GLAXO GROUP LIMITED (GB) | 2007-11-07 | — | — | EP | disclosed |
| US-20070244150-A1 | Muscarinic Acetylcholine Receptor Antagonists | GLAXO GROUP LIMITED | 2007-10-18 | — | — | US | disclosed |
| US-20070238752-A1 | Muscarinic Acetylcholine Receptor Antagonists | GLAXO GROUP LIMITED | 2007-10-11 | — | — | US | disclosed |
| US-7276521-B2 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-10-02 | — | — | US | disclosed |
| US-20070105895-A1 | Muscarinic acetycholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-05-10 | — | — | US | disclosed |
| WO-2006090142-A9 | l-{4- [ (l-CYCLOBUTYL-4-PIPERIDINYL) OXY] PHENYL] -4-{ [4- (METHYLSULFONYL) PHENYL]CARBONYL PIPERAZINE AS HISTAMINE H3 ANTAGONIST | GLAXO GROUP LTD (GB) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006090142-A1 | l-{4- [ (l-CYCLOBUTYL-4-PIPERIDINYL) OXY] PHENYL] -4-{ [4- (METHYLSULFONYL) PHENYL]CARBONYL PIPERAZINE AS HISTAMINE H3 ANTAGONIST | GLAXO GROUP LIMITED (GB) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238752-A1 | Muscarinic Acetylcholine Receptor Antagonists | CHRM3, CHRNG, CHRM2 | CHRM3 1/4885CHRM2 3/4885CHRM1 19/4885 |
| US-20070244150-A1 | Muscarinic Acetylcholine Receptor Antagonists | CHRM3, CHRNG, CHRM2 | CHRM3 1/4885CHRM2 3/4885CHRM1 19/4885 |
| US-20070105895-A1 | Muscarinic acetycholine receptor antagonists | CHRM3, CHRNA7, CHRNA2 | CHRM3 1/4885CHRM2 7/4885CHRM1 19/4885 |
| US-20100329996-A1 | Novel Combination of Therapeutic Agents | CHRNB1, CHRM3, CHRNB2 | CHRM3 2/4885CHRM2 10/4885CHRM1 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.